Form 4: Alignment Healthcare CEO Sells 90,000 Shares Under 10b5-1 Trading Plan

Alignment Healthcare's CEO, John E. Kao, sold 90,000 shares of common stock at an average price of $11.6521 per share, according to a recent SEC filing.

Summary

• John E. Kao, the CEO of Alignment Healthcare, sold 90,000 shares of common stock on December 11, 2024.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on March 14, 2024.
• The shares were sold at a weighted average price of $11.6521, with individual sales ranging from $11.44 to $11.81 per share.
• Following the transaction, Mr. Kao directly owns 2,745,253 shares and indirectly owns 2,363,100 shares through the JEK Trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for an executive stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing for insider transactions and is common for executives who use 10b5-1 plans to manage their stock sales. It does not indicate any specific trend in the healthcare industry.

Comparison to Industry Standards

• Executive stock sales are a common practice across all industries, including healthcare.
• The use of 10b5-1 plans is a standard method for executives to avoid accusations of insider trading.
• Comparable companies such as Humana, UnitedHealth Group, and CVS Health also see similar filings from their executives.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but it is unlikely to have a significant effect given the pre-planned nature of the transaction.

Key Dates

Keywords

SEC Form 4, insider trading, stock sale, 10b5-1 plan, Alignment Healthcare, ALHC, John E. Kao, executive stock